A promising pipeline of diverse molecular structures

Pipeline

QBiotics has identified significant unmet medical needs and market opportunities in a range of therapeutic areas.

Our current focus is on treating solid tumours and chronic wounds, with additional early programmes in antibiotics and anti-inflammatories.

Our anticancer drug candidate, tigilanol tiglate, is an intratumoural, oncolytic small molecule with potential in the treatment of a wide range of solid tumours. Tigilanol tiglate is currently in clinical Phase II development for the treatment of soft tissue sarcomas (USA) (awarded FDA Orphan Drug Designation) and head and neck cancers (UK and Australia).

Our wound healing drug candidate, EBC-1013, is a topically applied small molecule being developed for the treatment of a wide range of chronic and acute wounds and burns. EBC-1013 is soon to enter a clinical Phase I safety trial in patients with venous leg ulcers.

Human
Area
Molecule
Species
Indication
Trial registration #
Stage of Development
Preclinical
Phase I
Phase II
Phase IIb/III
Registration /
Marketing
Area:Oncology
Molecule:Tigilanol tiglate
Species:Human
Indication:Head & Neck Cancer
Trial registration #NCT05608876
% Stage of develepment
Species:Human
Indication:Soft Tissue Sarcoma
Trial registration #NCT05755113
FDA Orphan Drug Designation
% Stage of develepment
Area:Wounds
Molecule:EBC-1013
Species:Human
Indication:Venous Leg Ulcers
Trial registration #ACTRN12624000544572p
% Stage of develepment
Veterinary
Area
Molecule
Species
Indication
Clinical
Registration /
Marketing
Area:Oncology
Molecule:Tigilanol tiglate
Species:Canine
Indication:Mast Cell Tumour
STELFONTA® - marketed EU, UK, USA and Australia
% Stage of develepment
Species:Canine
Indication:Soft Tissue Sarcoma, Oral Melanoma
% Stage of develepment
Species:Equine
Indication:Sarcoid, Melanoma
% Stage of develepment
Area:Wounds
Molecule:EBC-1013
Species:Equine & Canine
Acute / Chronic wounds
Trial registration #
% Stage of develepment
Discovery
Area
Target
Collection
Lead optimisation
Initial
preclinical
Area:Antibiotics
Target:Multiple resistant organisms
% Stage of develepment
Area:Anti-inflammatories
Target: Dermatology
% Stage of develepment

Discover our portfolio

Oncology

Tigilanol tiglate is an intratumoural oncolytic small molecule with potential to treat a wide range of solid tumours.

Learn more

Wound Healing

EBC-1013 is our small molecule being developed for a wide range of chronic and acute wounds and burns.

Learn more

Preclinical

Our antibiotic discovery programme targets bacterial virulence.

Learn more

Sign up for company updates

Existing QBiotics Shareholder